LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: A novel pipeline for prioritizing cancer type-specific therapeutic vulnerabilities using DepMap identifies PAK2 as a target in head and neck squamous cell carcinomas.

    Sannigrahi, Malay K / Cao, Austin C / Rajagopalan, Pavithra / Sun, Lova / Brody, Robert M / Raghav, Lovely / Gimotty, Phyllis A / Basu, Devraj

    Molecular oncology

    2023  Volume 18, Issue 2, Page(s) 336–349

    Abstract: There is limited guidance on exploiting the genome-wide loss-of-function CRISPR screens in cancer Dependency Map (DepMap) to identify new targets for individual cancer types. This study integrated multiple tools to filter these data in order to seek new ... ...

    Abstract There is limited guidance on exploiting the genome-wide loss-of-function CRISPR screens in cancer Dependency Map (DepMap) to identify new targets for individual cancer types. This study integrated multiple tools to filter these data in order to seek new therapeutic targets specific to head and neck squamous cell carcinoma (HNSCC). The resulting pipeline prioritized 143 targetable dependencies that represented both well-studied targets and emerging target classes like mitochondrial carriers and RNA-binding proteins. In total, 14 targets had clinical inhibitors used for other cancers or nonmalignant diseases that hold near-term potential to repurpose for HNSCC therapy. Comparing inhibitor response data that were publicly available for 13 prioritized targets between the cell lines with high vs. low dependency on each target uncovered novel therapeutic potential for the PAK2 serine/threonine kinase. PAK2 gene dependency was found to be associated with wild-type p53, low PAK2 mRNA, and diploid status of the 3q amplicon containing PAK2. These findings establish a generalizable pipeline to prioritize clinically relevant targets for individual cancer types using DepMap. Its application to HNSCC highlights novel relevance for PAK2 inhibition and identifies biomarkers of PAK2 inhibitor response.
    MeSH term(s) Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/genetics ; Protein Serine-Threonine Kinases ; Head and Neck Neoplasms/drug therapy ; Head and Neck Neoplasms/genetics ; Cell Line, Tumor ; p21-Activated Kinases/genetics
    Chemical Substances Protein Serine-Threonine Kinases (EC 2.7.11.1) ; PAK2 protein, human (EC 2.7.11.1) ; p21-Activated Kinases (EC 2.7.11.1)
    Language English
    Publishing date 2023-12-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2415106-3
    ISSN 1878-0261 ; 1574-7891
    ISSN (online) 1878-0261
    ISSN 1574-7891
    DOI 10.1002/1878-0261.13558
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Determination of NUDT15 variants by targeted sequencing can identify compound heterozygosity in pediatric acute lymphoblastic leukemia patients.

    Yu, Chih-Hsiang / Chang, Ya-Hsuan / Wang, Der-Shiun / Jou, Shiann-Tarng / Lin, Chien-Yu / Lin, Kai-Hsin / Lu, Meng-Yao / Raghav, Lovely / Chang, Hsiu-Hao / Wu, Kang-Hsi / Chou, Shu-Wei / Ni, Yu-Ling / Lin, Dong-Tsamn / Lin, Shu-Wha / Chen, Hsuan-Yu / Yang, Yung-Li

    Scientific reports

    2020  Volume 10, Issue 1, Page(s) 14400

    Abstract: Mercaptopurine intolerance is an adverse effect of mercaptopurine administration in pediatric acute lymphoblastic leukemia. Recently, NUDT15 variants were identified as a major determinant of mercaptopurine intolerance. Two NUDT15 variants, c ... ...

    Abstract Mercaptopurine intolerance is an adverse effect of mercaptopurine administration in pediatric acute lymphoblastic leukemia. Recently, NUDT15 variants were identified as a major determinant of mercaptopurine intolerance. Two NUDT15 variants, c.36_37insGGAGTC and c.415C > T, are located on exons 1 and 3, respectively. Patients with heterozygous c.36_37insGGAGTC and c.415C > T can be either compound heterozygous with two variants on different alleles or heterozygous with both variants on the same allele. Because patients with biallelic NUDT15 variants are extremely sensitive to mercaptopurine, clinical identification of NUDT15 diplotype would be advantageous. A cohort of 37 patients with c.36_37insGGAGTC and c.415C > T NUDT15 variants were selected for haplotyping by targeted sequencing. NUDT15 complementary DNA was amplified and sequenced by 300-bp paired-end sequencing on Illumina MiSeq. Of the 37 patients carrying NUDT15 variants, 35 had heterozygous NUDT15*1/*2 variants and two had compound heterozygous NUDT15*3/*6 and NUDT15*2/*7 variants. These two patients with compound heterozygous variants could only tolerate low doses of mercaptopurine, similar to patients with homozygous NUDT15 variants. Targeted sequencing of NUDT15 cDNA can be used to determine NUDT15 diplotype and identify patients with compound heterozygous NUDT15 variants.
    MeSH term(s) Adolescent ; Alleles ; Antimetabolites, Antineoplastic/adverse effects ; Child ; Child, Preschool ; Cohort Studies ; Drug Resistance, Neoplasm/genetics ; Exons ; Female ; Haplotypes ; Heterozygote ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Infant ; Infant, Newborn ; Male ; Mercaptopurine/adverse effects ; Polymorphism, Genetic ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Pyrophosphatases/genetics ; Sequence Analysis, DNA/methods ; Taiwan/epidemiology
    Chemical Substances Antimetabolites, Antineoplastic ; Mercaptopurine (E7WED276I5) ; NUDT15 protein, human (EC 2.6.1.-) ; Pyrophosphatases (EC 3.6.1.-)
    Language English
    Publishing date 2020-09-01
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-020-71468-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma.

    Raghav, Lovely / Chang, Ya-Hsuan / Hsu, Yi-Chiung / Li, Yu-Cheng / Chen, Chih-Yi / Yang, Tsung-Ying / Chen, Kun-Chieh / Hsu, Kuo-Hsuan / Tseng, Jeng-Sen / Chuang, Cheng-Yen / Lee, Mei-Hsuan / Wang, Chih-Liang / Chen, Huei-Wen / Yu, Sung-Liang / Su, Sheng-Fang / Yuan, Shin-Sheng / Chen, Jeremy J W / Ho, Shinn-Ying / Li, Ker-Chau /
    Yang, Pan-Chyr / Chang, Gee-Chen / Chen, Hsuan-Yu

    Cancers

    2020  Volume 12, Issue 3

    Abstract: Risk factors including genetic effects are still being investigated in lung adenocarcinoma (LUAD). Mitochondria play an important role in controlling imperative cellular parameters, and anomalies in mitochondrial function might be crucial for cancer ... ...

    Abstract Risk factors including genetic effects are still being investigated in lung adenocarcinoma (LUAD). Mitochondria play an important role in controlling imperative cellular parameters, and anomalies in mitochondrial function might be crucial for cancer development. The mitochondrial genomic aberrations found in lung adenocarcinoma and their associations with cancer development and progression are not yet clearly characterized. Here, we identified a spectrum of mitochondrial genome mutations in early-stage lung adenocarcinoma and explored their association with prognosis and clinical outcomes. Next-generation sequencing was used to reveal the mitochondrial genomes of tumor and conditionally normal adjacent tissues from 61 Stage 1 LUADs. Mitochondrial somatic mutations and clinical outcomes including relapse-free survival (RFS) were analyzed. Patients with somatic mutations in the D-loop region had longer RFS (adjusted hazard ratio, adjHR = 0.18,
    Language English
    Publishing date 2020-03-23
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers12030755
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression

    Chen, Yi-ju / Roumeliotis, Theodoros I. / Chang, Ya-Hsuan / Chen, Ching-Tai / Han, Chia-Li / Lin, Miao-Hsia / Chen, Huei-Wen / Chang, Gee-Chen / Chang, Yih-Leong / Wu, Chen-Tu / Lin, Mong-Wei / Hsieh, Min-Shu / Wang, Yu-Tai / Chen, Yet-Ran / Jonassen, Inge / Ghavidel, Fatemeh Zamanzad / Lin, Ze-Shiang / Lin, Kuen-Tyng / Chen, Ching-Wen /
    Sheu, Pei-Yuan / Hung, Chen-Ting / Huang, Ke-Chieh / Yang, Hao-Chin / Lin, Pei-Yi / Yen, Ta-Chi / Lin, Yi-Wei / Wang, Renhong / Raghav, Lovely / Lin, Chien-Yu / Chen, Yan-Si / Wu, Pei-Shan / Lai, Chi-Ting / Weng, Shao-Hsing / Su, Kang-Yi / Chang, Wei-Hung / Tsai, Pang-Yan / Robles, Ana I. / Rodriguez, Henry / Hsiao, Yi-Jing / Chang, Wen-Hsin / Sung, Ting-Yi / Chen, Jin-Shing / Yu, Sung-Liang / Choudhary, Jyoti S. / Chin, Sen'itsu / Yang, Pan-Chyr / Chen, Yu-Ju

    Elsevier Inc. Cell. 2020 July 09, v. 182, no. 1 p.226-244.e17

    2020  

    Abstract: Lung cancer in East Asia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this demographically distinct disease, we performed a deep comprehensive proteogenomic ... ...

    Abstract Lung cancer in East Asia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this demographically distinct disease, we performed a deep comprehensive proteogenomic study on a prospectively collected cohort in Taiwan, representing early stage, predominantly female, non-smoking lung adenocarcinoma. Integrated genomic, proteomic, and phosphoproteomic analysis delineated the demographically distinct molecular attributes and hallmarks of tumor progression. Mutational signature analysis revealed age- and gender-related mutagenesis mechanisms, characterized by high prevalence of APOBEC mutational signature in younger females and over-representation of environmental carcinogen-like mutational signatures in older females. A proteomics-informed classification distinguished the clinical characteristics of early stage patients with EGFR mutations. Furthermore, integrated protein network analysis revealed the cellular remodeling underpinning clinical trajectories and nominated candidate biomarkers for patient stratification and therapeutic intervention. This multi-omic molecular architecture may help develop strategies for management of early stage never-smoker lung adenocarcinoma.
    Keywords adenocarcinoma ; biomarkers ; females ; genomics ; lung neoplasms ; lungs ; mutagenesis ; neoplasm progression ; patients ; phenotype ; proteomics ; therapeutics ; Taiwan ; lung cancer ; non-smoker ; proteogenomics ; phosphoproteomics ; APOBEC signature ; carcinogen signature ; subtyping ; MMP
    Language English
    Dates of publication 2020-0709
    Size p. 226-244.e17.
    Publishing place Elsevier Inc.
    Document type Article ; Online
    ZDB-ID 187009-9
    ISSN 1097-4172 ; 0092-8674
    ISSN (online) 1097-4172
    ISSN 0092-8674
    DOI 10.1016/j.cell.2020.06.012
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  5. Article ; Online: Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression.

    Chen, Yi-Ju / Roumeliotis, Theodoros I / Chang, Ya-Hsuan / Chen, Ching-Tai / Han, Chia-Li / Lin, Miao-Hsia / Chen, Huei-Wen / Chang, Gee-Chen / Chang, Yih-Leong / Wu, Chen-Tu / Lin, Mong-Wei / Hsieh, Min-Shu / Wang, Yu-Tai / Chen, Yet-Ran / Jonassen, Inge / Ghavidel, Fatemeh Zamanzad / Lin, Ze-Shiang / Lin, Kuen-Tyng / Chen, Ching-Wen /
    Sheu, Pei-Yuan / Hung, Chen-Ting / Huang, Ke-Chieh / Yang, Hao-Chin / Lin, Pei-Yi / Yen, Ta-Chi / Lin, Yi-Wei / Wang, Jen-Hung / Raghav, Lovely / Lin, Chien-Yu / Chen, Yan-Si / Wu, Pei-Shan / Lai, Chi-Ting / Weng, Shao-Hsing / Su, Kang-Yi / Chang, Wei-Hung / Tsai, Pang-Yan / Robles, Ana I / Rodriguez, Henry / Hsiao, Yi-Jing / Chang, Wen-Hsin / Sung, Ting-Yi / Chen, Jin-Shing / Yu, Sung-Liang / Choudhary, Jyoti S / Chen, Hsuan-Yu / Yang, Pan-Chyr / Chen, Yu-Ju

    Cell

    2020  Volume 182, Issue 1, Page(s) 226–244.e17

    Abstract: Lung cancer in East Asia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this demographically distinct disease, we performed a deep comprehensive proteogenomic ... ...

    Abstract Lung cancer in East Asia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this demographically distinct disease, we performed a deep comprehensive proteogenomic study on a prospectively collected cohort in Taiwan, representing early stage, predominantly female, non-smoking lung adenocarcinoma. Integrated genomic, proteomic, and phosphoproteomic analysis delineated the demographically distinct molecular attributes and hallmarks of tumor progression. Mutational signature analysis revealed age- and gender-related mutagenesis mechanisms, characterized by high prevalence of APOBEC mutational signature in younger females and over-representation of environmental carcinogen-like mutational signatures in older females. A proteomics-informed classification distinguished the clinical characteristics of early stage patients with EGFR mutations. Furthermore, integrated protein network analysis revealed the cellular remodeling underpinning clinical trajectories and nominated candidate biomarkers for patient stratification and therapeutic intervention. This multi-omic molecular architecture may help develop strategies for management of early stage never-smoker lung adenocarcinoma.
    MeSH term(s) Adenocarcinoma of Lung/genetics ; Adenocarcinoma of Lung/pathology ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Carcinogens/toxicity ; Cohort Studies ; Cytosine Deaminase/metabolism ; Disease Progression ; Far East ; Gene Expression Regulation, Neoplastic ; Gene Regulatory Networks ; Genome, Human ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Matrix Metalloproteinases/metabolism ; Mutation/genetics ; Principal Component Analysis ; Proteogenomics ; Smoking/genetics
    Chemical Substances Biomarkers, Tumor ; Carcinogens ; Matrix Metalloproteinases (EC 3.4.24.-) ; Cytosine Deaminase (EC 3.5.4.1)
    Language English
    Publishing date 2020-07-20
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 187009-9
    ISSN 1097-4172 ; 0092-8674
    ISSN (online) 1097-4172
    ISSN 0092-8674
    DOI 10.1016/j.cell.2020.06.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top